News and Awards

2025 UCLA has chosen PurposeBio as its sole early-stage technology for the prestigious JPM 2025 Biotech Showcase, highlighting the company's exceptional potential among the university's top four life sciences innovations8.

The selection underscores PurposeBio's promising deep-tech synthetic biology platform and its groundbreaking pre-clinical stage therapeutics for cardiometabolic research. By featuring PurposeBio at the J.P. Morgan Healthcare Conference, UCLA signals strong confidence in the startup's innovative scientific approach and potential for transformative medical advancements

2025 Purpose Bio invited and attending JPM 2025 Healthcare Conference
2023 U.S Department Of Defense awards and recognizes Purpose Bio for Innovation and Potential Impact, December, Washington D.C.
2023 Purpose Bio is a finalist at the LabCentral Golden Ticket competition, final pitch day on September 19th, Boston
Purpose Bio is invited to present at Bioventure Nexus and will present on Oct 6th 2023, at the Synthetic Biology track
2023 Purpose Bio is invited to present at the First Look Innovation Showcase of The Alliance For SoCal Innovation, celebrating the very early-stage startups commercializing deep tech and life science breakthroughs from SoCal’s top research institutions.
2023 Purpose Bio is attending SynBioBeta Conference in Oakland, May 23-25
2023 Purpose Bio is attending and presenting at the BIO CEO and Investor Conference, NYC Feb 6-9
2023 Purpose Bio is invited to present at the European Microbiome-Movement Drug Discovery Conference, London Jan 31-Feb 2

CEO, Founder Lital Gilad-Shaoulian will be presenting Purpose Bio's science on Feb 1st at 12:15pm

CEO, Founder Lital Gilad-Shaoulian will moderate an investor panel, discussing Investments in Microbiome Therapeutics Feb 1st at 4:30pm

2022 UCLA selects Purpose Bio as "Best, Most Investment-Worthy Startups spinning technology out of UCLA"

2022 Purpose Bio expands the partnership with UCLA by signing an additional exclusive license agreement, to broaden the IP and therapeutic pipeline

2021 Purpose Bio signs a global exclusive license agreement with UCLA